You are here

STTR Phase I: Overcoming Metabolic Pathway Limitations through De Novo Pathway Design for Terpenoid Biosynthesis

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 1321442
Agency Tracking Number: 1321442
Amount: $225,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: EB
Solicitation Number: N/A
Solicitation Year: 2012
Award Year: 2013
Award Start Date (Proposal Award Date): 2013-07-01
Award End Date (Contract End Date): 2014-06-30
Small Business Information
790 Memorial Drive Suite 102
Cambridge, MA 02139-4768
United States
DUNS: 968671797
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Ajikumar Parayil Kumaran
 (617) 299-8466
Business Contact
 Ajikumar Parayil Kumaran
Phone: (617) 299-8466
Research Institution
 Northwestern Unviersity
 Keith Tyo
1801 Maple Ave
Evanston, IL 60208-
United States

 () -
 Nonprofit College or University

This Small Business Innovation Research (STTR) Phase I project aims to develop a novel, high flux terpenoid precursor pathway by circumventing limitations of the bacterial methyl erythritol-phosphate (MEP) pathway for the renewable production of monoterpenoids. Monoterpenoids are natural chemical precursors for several consumer products, and many are produced via highly polluting chemical processes. In the proposed project the plan is to sidestep some of the MEP pathway limitations by designing de novo metabolic pathways. The designed/predicted enzymes will be characterized individually and assembled into a pathway. Further, multivariate-modular metabolic engineering (MMME) approaches will be used to assemble the upstream and downstream pathways to optimize the metabolic flux for the overproduction at commercially viable levels. The broader impact/commercial potential of this project, if successful, will be to develop a microbial monoterpenoid production platform from renewable sugars that will retain and develop sustainable manufacturing of monoterpenoid-derived products in the US. By this strategy, terpenoids can be made at much higher productivities than the native bacterial MEP pathway. While the immediate focus is on the $1B+ monoterpene/derivative market, this approach will benefit US manufacturing of all terpenoids, in total a $5B+ market. Overall, this project will provide a new sustainable production route for these natural chemicals.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government